

Electronic Acknowledgement Receipt

| | |
|---|---|
| EFS ID: | 5688858 |
| Application Number: | 10565545 |
| International Application Number: | |
| Confirmation Number: | 2393 |
| Title of Invention: | Use of substitute 2,4-bis (alkylamino) pyrimidines or quinzolines as antimicrobials |
| First Named Inventor/Applicant Name: | Sophie Marquis-Bienewald |
| Customer Number: | 00324 |
| Filer: | Joseph C. Suhadolnik/Andrea DeCecchis |
| Filer Authorized By: | Joseph C. Suhadolnik |
| Attorney Docket Number: | HM152292/APCT |
| Receipt Date: | 13-JUL-2009 |
| Filing Date: | 23-JAN-2006 |
| Time Stamp: | 15:15:29 |
| Application Type: | U.S. National Stage under 35 USC 371 |

Payment information:

| | |
|---|-----------------|
| Submitted with Payment | yes |
| Payment Type | Deposit Account |
| Payment was successfully received in RAM | \$810 |
| RAM confirmation Number | 1447 |
| Deposit Account | 031935 |
| Authorized User | |
| The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows: Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges) | |

File Listing:

| Document Number | Document Description | File Name | File Size(Bytes)/ Message Digest | Multi Part /.zip | Pages (if appl.) |
|-----------------|---|--------------------------|--|------------------|------------------|
| 1 | Request for Continued Examination (RCE) | 22927rcesb0030e_fill.pdf | 697481 8796a122079a03d46494d81030803e3f5f5298523f | no | 3 |

Warnings:**Information:**

| | | | | | |
|---|--|---------------------------------|--|-----|---|
| 2 | | 22927_resptofinalOA_4_13_09.pdf | 698935 040615a6a418d27dcb3992717228d5021bcf357b | yes | 9 |
|---|--|---------------------------------|--|-----|---|

Multipart Description/PDF files in .zip description

| Document Description | Start | End |
|--|-------|-----|
| Amendment Submitted/Entered with Filing of CPA/RCE | 1 | 1 |
| Claims | 2 | 4 |
| Applicant Arguments/Remarks Made in an Amendment | 5 | 9 |

Warnings:**Information:**

| | | | | | |
|---|-------------------------|--------------|--|----|---|
| 3 | Fee Worksheet (PTO-875) | fee-info.pdf | 30912 9c16d76d14e4977db414603a529a2d95f9f35d1 | no | 2 |
|---|-------------------------|--------------|--|----|---|

Warnings:**Information:**

| | |
|-------------------------------------|---------|
| Total Files Size (in bytes): | 1427328 |
|-------------------------------------|---------|

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.